Diclofenac Potassium for Oral Solution — Competitive Intelligence Brief

Diclofenac Potassium for Oral Solution (Diclofenac Potassium for Oral Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management / Rheumatology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Rheumatology Small molecule

Target snapshot

Diclofenac Potassium for Oral Solution (Diclofenac Potassium for Oral Solution) — Depomed. Diclofenac potassium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing pain and inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diclofenac Potassium for Oral Solution TARGET	Diclofenac Potassium for Oral Solution	Depomed	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Aspirin tablets	Aspirin tablets	PLx Pharma	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
ketorolac (Acular LS)	ketorolac (Acular LS)	Center For Excellence In Eye Care	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Loxoprofen sodium tablet	Loxoprofen sodium tablet	Sun Yat-sen University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Diclofenac 1%	Diclofenac 1%	Daré Bioscience, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Bromfenac Ophthalmic Solution B	Bromfenac Ophthalmic Solution B	Bausch & Lomb Incorporated	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Aspirin (acetylsalicylic acid)	Aspirin (acetylsalicylic acid)	Swedish Medical Center	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class